You searched for "ICS"
Two blue pills
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). If I were to say to you, ‘The Blue Pill’ I suspect you...Patient portals
In May 2012, the Department of Health published its information strategy ‘Power of information’ which aims to put us all in control of the health and care information we need [1]. As a part of its information strategy a key...Frailty in urology – part 1
Part 2 of this topic can be found here Statement of the problem Clinical frailty carries an increased risk of poor health outcomes. The pathological process resulting in frailty is often overlooked and elucidating its aetiology and natural history are...An inconvenient truth: reflections on the NHS
“What gets us into trouble is not what we don’t know. It’s what we know for sure that just ain’t so.” The above is a quote attributed to Mark Twain from the 2006 documentary, An Inconvenient Truth, which follows Al...Urology Podcasts and NotebookLM
Podcasts, downloadable or streamable digital audio / video shows, have surged in popularity over the last five years due to the ubiquity of smartphones, high-speed mobile networks, and accessible content creation technology. They offer on-the-go access to expert discussions, clinical...Bridging the gap: the role of ASiT and BSoT in inspiring the next generation of urologists
Urology is a highly technical, rapidly evolving specialty and yet under-represented. At a time of significant innovation driven by advances in minimally invasive surgery, endourology and robotics, it is more important than ever to ensure a strong pipeline of motivated...Keep patients at the heart of treatment decision
Rebecca Porta, Chief Executive of The Urology Foundation, and Chris Whitehouse, Chair of the Urology Trade Association, mark Urology Awareness Month. Rebecca Porta. Chris Whitehouse. Keep patients at the heart of treatment decision This September marked Urology Awareness Month (UAM),...
Anti-VEGF and PD-1 combinations in renal cell carcinoma
Over the past decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been central to treating renal cell carcinoma (RCC), with oncologists refining dosing strategies to balance treatment efficacy with quality of life (QoL). Recently, the introduction of...
